Ravi P Nargund

Ravi P Nargund

UNVERIFIED PROFILE

Are you Ravi P Nargund?   Register this Author

Register author
Ravi P Nargund

Ravi P Nargund

Publications by authors named "Ravi P Nargund"

Are you Ravi P Nargund?   Register this Author

55Publications

2415Reads

35Profile Views

Design and evaluation of novel tetracyclic benzofurans as palm site allosteric inhibitors of HCV NS5B polymerase.

Bioorg Med Chem Lett 2019 Dec 26;29(24):126104. Epub 2018 Oct 26.

Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2018.10.045DOI Listing
December 2019

Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.

ACS Med Chem Lett 2016 Dec 12;7(12):1107-1111. Epub 2016 Oct 12.

Departments of Medicinal Chemistry, Discovery Pharmaceutical Sciences, Pharmacokenetics Pharmacodynamics Drug Metabolism, Diabetes Research, and Cardiometabolic Disease, Merck & Co., Inc., MRL , 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.6b00314DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5150677PMC
December 2016

Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes.

ACS Med Chem Lett 2015 Aug 10;6(8):936-41. Epub 2015 Jul 10.

Departments of Medicinal Chemistry, Diabetes Biology, Pharmacology, Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Basic Pharmaceutical Sciences, Chemical Modeling and Informatics, and Process Research, Merck Research Laboratories , Rahway, New Jersey 07065, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.5b00207DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538435PMC
August 2015

Pyridinesulfonylureas and pyridinesulfonamides as selective bombesin receptor subtype-3 (BRS-3) agonists.

Bioorg Med Chem Lett 2011 Apr 25;21(7):2040-3. Epub 2011 Feb 25.

Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2011.02.011DOI Listing
April 2011

Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity.

J Med Chem 2006 Jul;49(14):4035-43

Merck Research Laboratories, P.O. Box 2000, Rahway, New Jersey 07065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm058241aDOI Listing
July 2006

Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands.

Bioorg Med Chem Lett 2006 Mar 20;16(5):1130-3. Epub 2005 Dec 20.

Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065-0900, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0960894X0501531
Publisher Site
http://dx.doi.org/10.1016/j.bmcl.2005.11.095DOI Listing
March 2006

Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists.

Biochemistry 2005 Aug;44(34):11329-41

Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi0501840DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2532597PMC
August 2005